Skip to main content

Table 2 Characteristics of fully published trials according to whether the study identifier is present

From: Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation

 

Presence or absence of study identifier in the published article

Yes (n = 71)

No (n = 18)

Study phase, n (%)

 Phase 1

17 (24)

12 (67)

 Phase 2

38 (54)

6 (33)

 Phase 3

16 (23)

0

Drug type, n (%)

 Immune checkpoint inhibitors

18 (25)

1 (6)

 Other anticancer drugs

53 (75)

17 (94)

 Sample size, median (interquartile range)

102 (53–345)

42 (37–56)

 Multi-country study, n (%)

46 (65)

5 (28)

 Author affiliation with industry, n (%)

71 (100)

16 (89)

 Statistically significant outcomeª, n (%)

17 (24)

0

 Reporting of adverse events, n (%)

71 (100)

18 (100)

 Selective outcome reporting, n (%)

8 (11)

7 (39)

  1. ªAt least 1 of the primary outcomes was statistically significant